“Medical Cannabis and Cannabinoids” is a peer-reviewed journal offering an international forum to present and discuss recent advances in the rapidly developing field of medical cannabis and cannabinoids.
Marijuana use is prevalent both in states where it is legal to some degree and in states where it is not. However, evidence suggests that many physicians may be unprepared for this reality.
There’s no official endorsement of medical cannabis for dementia, but with or without scientific data, more and more people are willing to investigate cannabis to treat their loved ones.
By Fred Gardner The International Cannabinoid Research Society (ICRS) has adopted the journal Cannabis and Cannabinoid Research (CCR) as its official publication. Dr. Daniele Piomelli, a pharmacologist at UC Irvine, edits the journal.
The press release from the publisher states that CCR is “extremely excited” by the affiliation. The release does not list clinical among the types of studies the ICRS has been “spearheading,” but does list “misuse potential.”
A note from the publisher of Alternative Therapies in Health and Medicine introduces “the first issue of Beyond CBD, a special supplement.” They’re obviously planning more. The lead article, “The Endocannabinoid System and its Modulation by Cannabidiol (CBD)” by Jamie Corroon, ND, MPH, and Jake F. Felice, ND, LMP is the most thorough and well-written overview we’ve seen.
Although it’s entitled “How Legalization Changed Humboldt County Marijuana,” Emily Witt’s article in the New Yorker is not about new plant varieties but about new social realities.
Eating mushrooms may reduce the risk of cognitive impairment, according to a study published in the Journal of Alzheimer’s Disease.
EPIDIOLEX®, a cannabidiol oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement Administration. But CBD remains on Schedule I, due to its supposed abuse liability.
Dr. Ethan Russo’s research on the Grand Unified Theory (GUT) that discusses how cannabis-based treatment and nutritional approaches can address five conditions that are difficult to treat with conventional medicine.
In this seminal study, Dr. Dedi Meiri and his team from Israel enhance our knowledge of the content, effect, and variability of cannabinoids across 36 individual cannabis cultivars.
SCC Board Members oppose several key provisions JAMA wants the state medical boards to adopt.
Ethan Russo, MD, is a board-certified neurologist and psychopharmacology researcher. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences. He is currently Past-President of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines.